Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon.
Preclinical drug safety evaluation studies, typically conducted in two or more animal species, reveal and define dose-dependent toxicities and undesirable effects related to pharmacological mechanism of action. Idiosyncratic toxic responses are often not detected during this phase in development due to their relative rarity in incidence and differences in species sensitivity. This paper reviews and discusses the metabolic idiosyncratic toxicity and species differences observed for the experimental non-benzodiazepine anxiolytic, panadiplon. This compound produced evidence of hepatic toxicity in Phase 1 clinical trial volunteers that was not predicted by rat, dog or monkey preclinical studies. However, subsequent studies in Dutch-belted rabbits revealed a hepatic toxic syndrome consistent with a Reye's Syndrome-like idiosyncratic response. Investigations into the mechanism of toxicity using rabbits and cultured hepatocytes from several species, including human, provided a sketch of the complex pathway required to produce hepatic injury. This pathway includes drug metabolism to a carboxylic acid metabolite (cyclopropane carboxylic acid), inhibition of mitochondrial fatty acid beta-oxidation, and effects on intermediary metabolism including depletion of glycogen and disruption of glucose homeostasis. We also provide evidence suggesting that the carboxylic acid metabolite decreases the availability of liver CoA and carnitine secondary to the formation of unusual acyl derivatives. Hepatic toxicity could be ameliorated by administration of carnitine, and to a lesser extent by pantothenate. These hepatocellular pathway defects, though not directly resulting in cell death, rendered hepatocytes sensitive to secondary stress, which subsequently produced apoptosis and hepatocellular necrosis. Not all rabbits showed evidence of hepatic toxicity, suggesting that individual or species differences in any step along this pathway may account for idiosyncratic responses. These differences may be roughly applied to other metabolic idiosyncratic hepatotoxic responses and include variations in drug metabolism, effects on mitochondrial function, nutritional status, and health or underlying disease.
Ulrich
R G
RG
Cellular and Molecular Toxicology Abbott Laboratories Department 463, AP13A100 Abbott Park Road Abbott Park, IL 60064, USA. roger.ulrich@abbott.com
Bacon
J A
JA
Brass
E P
EP
Cramer
C T
CT
Petrella
D K
DK
Sun
E L
EL
D000818:Animals; D014151:Anti-Anxiety Agents / Q000378:metabolism* / Q000633:toxicity*; D002331:Carnitine / Q000378:metabolism / Q000494:pharmacology; D015687:Cell Hypoxia; D002478:Cells, Cultured; D056486:Chemical and Drug Induced Liver Injury / Q000378:metabolism* / Q000473:pathology / Q000517:prevention & control; D017321:Clinical Trials, Phase I as Topic; D003065:Coenzyme A / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D010069:Oxadiazoles / Q000378:metabolism* / Q000633:toxicity*; D010205:Pantothenic Acid / Q000378:metabolism / Q000494:pharmacology; D011810:Quinoxalines / Q000378:metabolism* / Q000633:toxicity*; D011817:Rabbits; D012202:Reye Syndrome / Q000139:chemically induced / Q000378:metabolism; D013045:Species Specificity
D014151:Anti-Anxiety Agents; D010069:Oxadiazoles; D011810:Quinoxalines; D010205:Pantothenic Acid; D002331:Carnitine; D003065:Coenzyme A; C069443:panadiplon